Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KCUFS
ADC Name
36924655 ADC 9
Synonyms
ADC 9
   Click to Show/Hide
Organization
Seoul National University.
Drug Status
Investigative
Drug-to-Antibody Ratio
3.75
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Site-specific conjugation via re-bridging.
ADC-specific functional property(2027 Update)
Bystander Killing Effect
Click To Hide/Show 1 ADC-specific functional property Data
Bystander Killing Effect Description Reference
yes
Subsequently, we conducted the co-culture of HER2-positive and HER2-negative cell lines at varying ratios,[52] followed by treatment with the abovementioned ADCs. The viability of HER2-negative cells in the co-culture system was measured by detecting the GFP fluorescence intensity. The results showed that three ADCs with exatecan derivatives payload killed both NCI-N87 and MDA-MB-231/GFP cells, but T-DM1 (negative control) did not, which was consistent with the result observed by fluorescence microscopy

   Click to Show/Hide
[1]
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.091
nM
CVCL_0418
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.331
nM
CVCL_1603
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.091 nM Low HER2 expression (HER2+)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-453 cell.
In Vitro Model Breast adenocarcinoma MDA-MB-453 cells CVCL_0418
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.331 nM High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the nci-n87 cell.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors